Search Results
Your search for ,HIS matches 4562 pages
Showing 501 - 550Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology and Association for Clinical Oncology, issued the following statement after President Joseph R. Biden’s State of the Union address earlier this week. “ASCO applauds...
Carl H. June, MD, Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) will award Carl H. June, MD, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting 2023, taking place from April 14 to 19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in...
Defensive Beliefs May Prevent Individuals From Partaking in Screening for Colorectal Cancer
Investigators have revealed that individuals who react defensively to an invitation for colorectal cancer screening may be less likely to take part, according to a new study published by Clarke et al in Cancer. Background Colorectal cancer is one of the most treatable cancer types—especially if...
Challenges of Accurately Identifying HER2-Low Breast Cancers
The newly identified category of “HER2-low” breast cancer has raised many new issues in this malignancy now that the DESTINY Breast-041 trial determined that fam-trastuzumab deruxtecan-nxki (T-DXd) may effectively treat this tumor. Among the issues are challenges in accurately identifying just...
Adjuvant Osimertinib Significantly Improves Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC
The EGFR tyrosine kinase inhibitor osimertinib may improve rates of disease-free survival and reduce the risk of recurrence in patients with resected, EGFR-mutant non–small cell lung cancer (NSCLC), according to a new exploratory analysis of the ADAURA trial published by Roy S. Herbst, MD, PhD,...
Immunotherapy Combined With Targeted Therapy in Patients With BRAF V600E–Mutated Colorectal Cancer
In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, researchers discovered that a combination regimen of dabrafenib, trametinib, and spartalizumab resulted in long-lasting responses. The study findings published by ...
Undaunted
Soon after my marriage, in 2003, I noticed swelling in the glands around my throat. Although I otherwise felt fine, I went to see my primary care physician for a checkup and a blood test. The results of the test showed that I had an abnormally high number of lymphocytes circulating in my...
Atrium Health and Wake Forest University School of Medicine Cancer Program Appoint New Director
Atrium Health recently announced that Ruben A. Mesa, MD, FACP, has been named President and Executive Director of its cancer service line—which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center—and Vice Dean for Cancer Programs at...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Remembering Breast Cancer Pioneer Isaac Craig Henderson, MD
Isaac Craig Henderson, MD, passed away at the age of 81 at his home in San Francisco on December 26, 2022, after a brief illness. Dr. Henderson was an internationally known medical oncologist who specialized in breast cancer, beginning his career at Harvard’s then-designated Sidney Farber Cancer...
Northwell Receives Gift From Trustee Roy J. Zuckerberg to Create First Cancer Hospital and Cancer Campus on Long Island
Northwell Health recently announced a gift from longtime trustee Roy J. Zuckerberg to create the R.J. Zuckerberg Cancer Hospital at Long Island Jewish (LIJ) Medical Center—Long Island’s first cancer hospital—and to establish the R.J. Zuckerberg Cancer Center, Northwell’s largest ambulatory cancer...
How Experts Treat Mantle Cell Lymphoma in First Complete Response
Options are growing in the treatment of mantle cell lymphoma after complete response. At the 2022 Pan Pacific Lymphoma Conference,1 the use of these newer strategies in older patients was discussed by Brad S. Kahl, MD, Professor of Medicine and Director of the Lymphoma Service at Washington...
Being on the Other Side: An Oncologist’s Perspective on Grieving
As an oncologist, I had cared for patients facing grave illness and death. I imagined the loss of loved ones and expected grief to be an unbearable sadness, most poignant in the earliest days and lessening with time. I somehow expected that counseling people who grieved would make me more prepared. ...
A Serendipitous Opportunity Steers a Theater Major Into Oncology
Lymphoma expert Jeremy S. Abramson, MD, was born in Westchester County, New York, but soon after, his family relocated to Bergen County, New Jersey, where he spent his formative years. “I attended Tenafly High School and had dual passions: one was the natural sciences and the other on the...
Northwell Cancer Institute Welcomes New Chief of Hematologic Malignancies
Northwell Health recently appointed Douglas Gladstone, MD, a leader in hematology and medical oncology, as Chief of Hematologic Malignancies at the Northwell Health Cancer Institute. Prior to joining Northwell, Dr. Gladstone served for 14 years as Clinical Director of the outpatient bone marrow...
Yale Cancer Center Presents 2022 Research Awards
Yale Cancer Center’s Annual Conclave, held on January 5, recognized the scientific and clinical accomplishments of the Center’s faculty and staff in 2022. Eric Winer, MD, hosted the event and presented research awards in four categories: The Yale Cancer Center Population Science Research Prizes...
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Expert Point of View: Mrinal S. Patnaik, MBBS
Mrinal S. Patnaik, MBBS, Chair of the Acute Leukemia and Myeloid Neoplasms Group and Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program at the Mayo Clinic, Rochester, Minnesota, offered his thoughts on the phase II study findings of ruxolitinib’s efficacy...
Study Finds Immune Checkpoint Inhibitors Safe and Effective for Patients Living With HIV Who Have NSCLC
Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.1 Findings from the first matched cohort to compare clinical...
ASH 2022: Multiple Myeloma Highlights
The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition was full of interesting abstracts in multiple myeloma. In addition to full coverage of several important presentations, The ASCO Post offers readers quick takes on some studies that could be practice-changing and others...
Addressing the Continued Existence of Racial Inequities in Cancer Care
The opportunity to write this commentary on cancer disparities comes at a sorrowful time for me. Despite practicing as a surgical oncologist for more than 20 years and understanding the unequal burden that cancer visits on the Black community, I was woefully unprepared for the premature death of my ...
Ensuring a More Diverse, Equitable, and Inclusive Workforce Within the SWOG Cancer Research Network
For more than 2 decades, Don S. Dizon, MD, FACP, FASCO, has devoted his medical career to the care of women’s cancers and the sexual health of cancer survivors of all genders and sexual identities. Early in his career, Dr. Dizon founded the Center for Sexuality, Intimacy, and Fertility at Women...
Reminders Based on Machine-Learning Algorithms May Improve End-of-Life Care for Patients With Cancer
Electronic nudges delivered to health-care clinicians based on a machine-learning algorithm capable of predicting mortality risk quadrupled rates of conversations with patients about their end-of-life care preferences, according to a new study published by Manz et al in JAMA Oncology. The study...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
New AI-Based Biomarker May Help Predict Immunotherapy Response for Patients With NSCLC
Researchers have discovered a new artificial intelligence (AI)-derived biomarker that uses routine imaging scans to help predict which patients with non–small cell lung cancer (NSCLC) will respond to immunotherapy, according to a novel study published by Alilou et al in Science Advances. The...
Prostate Cancer Screening Among Primary Care Providers
Investigators recently examined prostate cancer screening among primary care providers and found that screening tests were frequently used—even when they provide little value to patients, according to a new study published by Gillette et al in the Journal of the American Board of Family Medicine....
Sotorasib Shows Clinically Meaningful Activity Among Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
The KRAS G12C inhibitor sotorasib demonstrated clinically meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C–mutated metastatic pancreatic cancer, accordi�ng to a novel study published by Strickler et al in The New England Journal of...
Eyal Gottlieb, PhD, to Join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center recently announced that Eyal Gottlieb, PhD, has been named the institution’s Vice President for Research. In this role, Dr. Gottlieb will oversee laboratory science departments leading innovative discovery and translational research across a variety ...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
2022 San Antonio Breast Cancer Symposium Award Recipients Announced
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, honored two researchers for their significant contributions to breast cancer research at the 2022 SABCS. 2022 AACR Distinguished Lectureship in Breast Cancer Research Charles ...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
How Do You Move Forward With a Life You Didn’t Choose After a Cancer Diagnosis?
“I was in bed in the surgical wing of Duke University Hospital when the doctor popped his head in and smiled apologetically before flicking on the fluorescent lights. It was 4:00 AM, the end of my second night in the hospital, but nobody sleeps in the conventional sense,” writes Kate Bowler in the...
Risk of Adverse Side Effects From Cancer Immunotherapy May Be Higher in Patients With Certain Inherited Genetic Variations
Even as they’ve revolutionized cancer treatment, immune checkpoint inhibitors have been shown to produce a range of adverse immune-related side effects. Researchers have now identified inherited genetic variations that may place patients at high risk for complications when undergoing treatment with ...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Modakafusp Alfa May Be Effective at Treating Patients With Multiple Myeloma
The novel drug modakafusp alfa has shown early promise in combating relapsed/refractory multiple myeloma, according to new findings presented by Vogl et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 565). Background Modakafusp alfa is a fusion protein...
Francesco Maura, MD, on Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated With Targeted Immunotherapy
Francesco Maura, MD, of the University of Miami, Sylvester Comprehensive Cancer Center, discusses his team’s findings in which they defined a comprehensive catalogue of genomic determinants of response to DKRd (carfilzomib, lenalidomide, dexamethasone) in newly diagnosed multiple myeloma. The...
Genetic Profiling May Identify Patients With Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-Conserving Surgery
Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had similar rates of local recurrence independent of whether they received adjuvant radiation therapy after breast-conserving surgery, according to findings presented by Karlsson et al at the 2022 ...
Putting the Patient at the Center: The Career of Jeffery Ward, MD, FASCO
Editor’s Note: ASCO was deeply saddened by the news that Dr. Jeff Ward passed away on November 3, 2022. In an interview with Dr. Ward this past summer, published in ASCO Connection (August 30, 2022), ASCO recognized Dr. Ward’s commitment to exceptional patient care and public advocacy. An...
I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
World Travel Helped Brittany L. Bychkovsky, MD, MSc, Shape Her Global Commitment to Breast Cancer Care
Breast cancer specialist Brittany L. Bychkovsky, MD, MSc, grew up primarily in Kansas; however, given that her father was a pilot, her childhood was not wholly centered in the Sunflower State. “When I was 12 years old, my mom, who was a schoolteacher, was diagnosed with stage III breast cancer. Her ...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Michael A. Caligiuri, MD, Traveled From Humble Beginnings to a Notable Career as an Oncology Leader
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Michael A. Caligiuri, MD, a physician-scientist who currently serves as President of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief...
Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer
The use of circulating tumor cell counts to guide the choice between chemotherapy and endocrine therapy as first-line treatment for patients with metastatic, estrogen receptor–positive, HER2-negative breast cancer provided overall survival benefits compared with physician’s choice of treatment,...
Adding Capivasertib to Fulvestrant May Improve Progression-Free Survival in Patients With Advanced Hormone Receptor–Positive Breast Cancer
In patients with hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitors, the addition of the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant, according to results...
How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia
Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...
T-DXd Yields Superior Outcomes Over Chemotherapy-Based Regimens in Patients Previously Treated With T-DM1: DESTINY-Breast02
Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine (T-DM1), according to results from ...
ASTRO Celebrates Contributions to Radiation Oncology With 2022 Gold Medals and Other Awards
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2022 Gold Medal awards and other high-profile honors during an awards ceremony at the 2022 ASTRO Annual Meeting in San Antonio. ASTRO Gold Medal Wendell R. Lutz, PhD, and Tim R. Williams, MD, FASTRO, were awarded...
